Articles

Patients with type 1 diabetes who have been treated with intensive therapy have significantly lower incidences of retinopathy progression up to ten years, according to study results published in the December issue of the Archives of Ophthalmology.

Besifloxacin ophthalmic suspension 0.6% (Bausch & Lomb) has been recommended by the FDA for the treatment of bacterial conjunctivitis.

Gingko biloba extract (GBE) has an application in preventing steroid-induced ocular hypertension, according to study results published in the December issue of the Archives of Ophthalmology.

New imaging techniques are allowing more objective quantification of glaucoma diagnosis and progression, according to study results published online ahead of print by the British Journal of Ophthalmology.

Rolf Schwind, CEO of Schwind Eye Tech Solutions, has been presented with the Gusi Peace Prize 2008 in a ceremony held on November 24th in Manila, the Philippines.

Religiously-motivated fasting may affect glaucoma medication compliance rates, according to study results presented at the annual meeting of the American Academy of Ophthalmology (AAO).

Topical Endoscopic Fundal Imaging (TEFI) offers a rapid, comprehensive and non-invasive method of monitoring retinal disease progression, according to a study published in the December issue of Investigative Ophthalmology and Visual Science.

Azarga (brinzolamide 10mg/ml and timolol 5mg/ml fixed combination) has been approved by the European Medicines Agency (EMEA) for decreasing intraocular pressure (IOP) in adult patients with open-angle glaucoma or ocular hypertension after failure of monotherapy, according to an announcement from Alcon, Azarga's manufacturer.

Xibrom (bromfenac sodium ophthalmic solution) 0.09% (ISTA Pharmaceuticals, Inc.) achieved the primary endpoint of its Phase III trial: absence of ocular inflammation 15 days postoperatively.

Avastin (bevacizumab; Genentech) increases the ease of vitrectomy in severe proliferative diabetic retinopathy (PDR), according to a study published in the July issue of Clinical and Experimental Ophthalmology.

The lack of experience with evidence-based guidelines may be the reason for excessive follow-up after screening for hydroxychloroquine retinopathy, according to study results published in the December issue of the British Journal of Ophthalmology.

The BD range of Atomic Edge Limbal Relaxing Incision (LRI) knives for surgical correction of astigmatism has been launched by BD Medical. The knives, which feature a retractable safety shield, use single-crystal silicon, offering high performance at low cost.

The Pascal dynamic contour tonometer (DCT) and Reichert ocular response analyser (ORA) are the best tools for measuring corneal-compensated intraocular pressure (IOPcc) in patients with keratoconus (KC), according to study results published in the British Journal of Ophthalmology, December.

When using bevacizumab to treat choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD), a loading dose (LD) of bevacizumab is more effective than an as-needed (PRN) dosing schedule, according to study results published in the December issue of the British Journal of Ophthalmology.

Biaxial microincision cataract surgery (B-MICS) is more successful than traditional cataract surgery in improving optical performance and reducing higher order aberrations, according to study results published in the December issue of the British Journal of Ophthalmology.

Pegaptanib sodium therapy is safe in patients with neovascular age-related macular degeneration (NV-AMD) up to three years, according to study results published in the December issue of the British Journal of Ophthalmology.

Paediatric strabismus, particularly exotropia, increases the likelihood of psychiatric disease in later life, according to study results published in the November issue of Pediatrics.

A multimedia campaign may be the best way to raise glaucoma awareness in the UK, according to study results published in the December issue of the British Journal of Ophthalmology.

It is possible to administer verteporfin and ranibizumab on the same day without adverse events, according to study results published in the December issue of the British Journal of Ophthalmology.

The most recent featured discussion on the European Ophthalmology forum was on the topic of patient numbers

Professor Gerd U. Auffarth petitions the European Parliament for the introduction of co-pay schemes for cataract patients in the EU

OTE's Victoria Farrell interviews Cambodian paediatric ophthalmologist Phara Khauv to find out how an ORBIS initiative has impacted his practice in a vastly underserved country.

A series of debates on the most relevant, and most controversial, topics in ophthalmology, in which today's most eminent ophthalmologists argue for the validity of their differing opinions and practices.

HOYA Surgical Optics has been distributing IOLs to ophthalmic surgeons in Europe since 2003. The name HOYA, however, represents more than just IOLs; the firm has a long tradition in high tech optics…

The Phase I three-year feasibility study of the Argus II Retinal Implant for Retinitis Pigmentosa (RP) will be expanded to enrol more patients in Europe, according to an announcement from Second Sight Medical Products, the implant's manufacturer.

An ophthalmology network, aiming to prevent loss of vision across the country, has been established in Wales.

The growing understanding that glaucoma is a neurodegenerative rather than ocular disease is to be the principal topic of discussion of the annual Glaucoma Research Foundation (GRF) benefit, to be held January 28 2009 in San Francisco, California, US.

The methods used to manage glaucoma vary widely across the United Kingdom, according to study results published in the November issue of Eye.

STAAR Surgical has created the Collamer Accommodating Study Team (CAST), a group of seven ophthalmologists who will investigate the accommodative properties of STAAR's Collamer intraocular lens (IOL).

The Phase IIb trial assessing the safety and efficacy of microplasmin in patients, showed complete resolution of vitreomacular traction or macular hole without need for vitrectomy surgery, according to a statement from the trial sponsor, ThromboGenics NV.